William E. Solander

William E. Solander


Partner, New York

Bill Solander is a first-chair trial lawyer who hasn’t forgotten the importance of knowing his cases intimately. For pharmaceutical clients as well as those in other industries, he brings a hands-on style to high-stakes patent disputes, with particularly deep experience in ANDA litigation.

Mentored by the renowned patent litigator Robert Baechtold until his retirement, Bill has earned his own “fantastic reputation” as “a truly excellent patent litigator.”(Chambers USA). He has led cases involving subject matter as varied as prescription antiarrhythmic drugs, protein synthesis, new battery technologies, and prescription sleep aids, and he has secured victories in an equally wide variety of forums, including federal district and appellate courts, the Patent Trial and Appeal Board, and civil arbitrations.

Bill has also developed significant knowledge of IP laws and civil justice systems outside the United States, and frequently counsels clients who seek his strategic advice in connection with business and legal activities in foreign jurisdictions. He has been involved with trial teams on litigation in Australia, Canada, Germany, Israel and the UK, among other countries.

Bill speaks and writes frequently on litigation strategy, polymorph patents, and Hatch-Waxman litigation.

Case Highlight
LEO Pharmaceutical Products, Ltd. v. Rea
Federal Circuit (2013)

At the Federal Circuit, Bill secured a reversal of a finding by the Board of Patent Appeals and Interferences that a patent covering LEO Pharma’s topical antipsoriatic medication Taclonex was obvious. Applying the “substantial evidence” standard of review, the appellate panel noted that LEO Pharma’s burden was “a challenging one,” but determined that Bill and his team had met it.
What Others Say
  • “William Solander is highly intelligent, always reachable, and has excellent communication skills. He is an outstanding lawyer, is flexible and adaptable, and has the clients business in focus” (Best Lawyers in America 2014)
  • “Bill Solander is an insightful patent litigator with sound judgment who is capable of achieving effective results when solving legal and business issues” (Best Lawyers in America 2014)
  • “fantastic reputation” (Chambers USA 2013)
  • “terrific – he really gets into the case, knows the science, is up to date on the law and works well with witnesses” (Chambers USA 2012)
  • “a truly excellent patent litigator” (Chambers USA 2011)
  • “diligent lawyer” and [offers] “outstanding communication skills, a strong, strategic approach and a great understanding of the science” (IAM 250 The World’s Leading Patent Litigators 2011)
  • "a tough, in-the-trenches style litigator” (IAM 250 Life Sciences 2010)
  • "a litigator with great courtroom instincts" (Chambers USA 2008)
Representative Matters
  • Hoechst GmbH against Genentech, Inc., in an arbitration before the ICC International Court of Arbitration concerning royalties due under a terminated license involving eukaryotic protein expression technologies and Sanofi-Aventis Deutschland GmbH against Genentech and Biogen-IDEC on patents covering those technologies.
  • LEO Pharma against Tolmar Inc. and Perrigo Inc. on patents relating to Taclonex, a topical anti-psoriatic medication.
  • Sepracor Pharmaceuticals against Sandoz Inc., et al. on patents relating to Clarinex®, an allergy medication.
  • Sanofi against Sandoz Inc, et al. on a patent relating to Ambien CR®, a sleeping aid.
  • Sanofi v. Sandoz Inc., et al. on a patent relating to Eloxatin®, a platinum-containing anti-cancer drug.
  • Novartis Pharmaceuticals Corporation against Mylan Pharmaceuticals on a patent relating to Femara®, an aromatase inhibitor.
  • Bristol-Myers Squibb against Repligen in an inventorship suit relating to Bristol-Myers Squibb’s protein-fusion drug Orencia®.
  • Sanofi and Bristol-Myers Squibb against Apotex, et al. on patents covering Plavix®, a leading anti-thrombotic agent.
  • Sanofi and Bristol-Myers Squibb against Sun Pharmaceuticals on a patent relating to the crystalline form of the active ingredient in Plavix®.
  • Novartis Pharmaceuticals Corporation against Dr. Reddy’s Laboratories Ltd. on patents covering Lamisil®, and anti-fungal medicine.
  • Bristol-Myers Squibb against Rhone-Poulenc Rorer, Inc. et al. on patents relating to semi-synthetic process technology for making Taxol®.
  • Yamanouchi against Danbury Pharmacal on a patent relating to Pepcid®, an anti-ulcer drug.
Events / Publications
News & Press